Haemonetics Corp
haemonetics.comWhat Do They Do?
Sells plasma collection systems and donor software to plasma centers, blood-collection equipment to blood centers, and patient-care technologies to hospitals.
10-K for FY2026, filed May 20, 2026Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our…View ↗
Our Plasma business offers automated plasma collection systems, donor management software and supporting software solutions that enable…View ↗
Our Blood Center business offers a range of products and technologies to help blood centers optimize their blood collections, improve donor…View ↗
Hospitals are called upon to provide the highest standard of patient care while at the same time reducing operating costs. Haemonetics’…View ↗
How Do They Make Money?
Plasma centers, blood centers and hospitals buy equipment and disposable products; product sales are completed at shipment or delivery. The company also earns fees for maintenance and software services over time, with some software charges tied to use.
10-K for FY2026, filed May 20, 2026Our Plasma business offers automated plasma collection systems, donor management software and supporting software solutions that enable…View ↗
Our Blood Center business offers a range of products and technologies to help blood centers optimize their blood collections, improve donor…View ↗
Hospitals are called upon to provide the highest standard of patient care while at the same time reducing operating costs. Haemonetics’…View ↗
The majority of the Company’s performance obligations related to product sales are satisfied at a point in time. Product revenue consists…View ↗
To a lesser extent, the Company enters into other types of contracts including certain software licensing arrangements to provide software…View ↗
-
10-K for FY2026, filed May 20, 2026
FY2026 revenue by reportable segment ↗
$1.3B
-
10-K for FY2026, filed May 20, 2026
$1.3B ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Plasma
Sold outright
10-K for FY2026, filed May 20, 2026 |
39% |
Plasma, FY2026
$524.5M Sources
|
Sold outright |
|
Blood Center
Sold outright
10-K for FY2026, filed May 20, 2026 |
17% |
Blood Center, FY2026
$221.3M Sources
|
Sold outright |
|
Hospital
Sold outright
10-K for FY2026, filed May 20, 2026 |
44% |
Hospital, FY2026
$588.3M Sources
|
Sold outright |
Who Are Their Customers?
Sells through its own sales force and independent distributors to plasma companies, blood collection groups, and hospitals and related healthcare organizations.
10-K for FY2026, filed May 20, 2026We market and sell our products in approximately 90 countries through a combination of our own direct sales force (including full-time…View ↗
10-K for FY2026, filed May 20, 2026
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents and…View ↗
Do Revenues Turn Into Profits?
Yes. It kept 7 cents of every revenue dollar as net income in FY2026 and turned 20 cents into free cash flow.
10-K for FY2026, filed May 20, 2026
$156.7MView ↗
10-K for FY2026, filed May 20, 2026
$97.3MView ↗
10-K for FY2026, filed May 20, 2026
$260.4MView ↗
How Are They Changing?
-
Aug 6, 2026
Raises fiscal 2027 revenue guidance
Raised reported revenue growth guidance from 4 - 7% to 5 - 8%.
Sources
8-K, filed Aug 6, 2026
4 - 7% 5 - 8% 53rd week impactView ↗
Growing. Revenue grew 34% in 4 years, from $993.2M in FY2022 to $1.3B in FY2026, about 8% a year.
Whole blood products
Blood Center has exited whole blood products: the older report describes manual whole-blood collection sets, while the latest report says the product line was divested.
10-K for FY2023, filed May 22, 2023 10-K for FY2026, filed May 20, 2026Blood Center Products — We offer automated blood component systems to blood centers to collect blood products efficiently and cost…View ↗
Hospital product range
The Hospital portfolio description adds sensor-guided technologies and esophageal protection; the older overview listed hemostasis management, vascular closure, cell salvage and transfusion management.
10-K for FY2023, filed May 22, 2023 10-K for FY2026, filed May 20, 2026Hospitals are called upon to provide the highest standard of patient care while at the same time to reduce operating costs. Haemonetics’…View ↗
Hospitals are called upon to provide the highest standard of patient care while at the same time reducing operating costs. Haemonetics’…View ↗
Who Do They Compete With?
Competes with Terumo BCT, Fresenius, Abbott Laboratories, Nigale, Scinomed, Cordis, Teleflex, Boston Scientific, Werfen, Diagnostica Stago, Sysmex, HemoSonics, LivaNova, Medtronic, WellSky, SSC Soft, Cerner, Clinsys, MSoft, and MAK Systems
10-K for FY2026, filed May 20, 2026In addition, we face competition from several large global companies with product offerings similar to ours. Terumo Blood and Cell…View ↗
Loading...
